noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Waystar Holding Corp.

Waystar Introduces Industry’s First AI Solution Addressing Widespread[...]
Oak Ridge National Laboratory

She beat cancer, now she safeguards isotopes that fight it
Oak Ridge National Laboratory

Ann Weaver appointed Deputy for Operations at Oak Ridge National Laboratory

Healthcare

Nuvalent Inc.

04/07/2026 | Press release | Distributed by Public on 04/07/2026 04:33

Material Event (Form 8-K)

Item 8.01. Other Events.

On April 7, 2026, Nuvalent, Inc. announced the submission of its New Drug Application to the U.S. Food and Drug Administration for neladalkib in tyrosine kinase inhibitor pre-treated advanced ALK-positive non-small cell lung cancer.

Nuvalent Inc. published this content on April 07, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on April 07, 2026 at 10:34 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]